It is well known that phytochemicals such as curcumin possess great potential to support a healthy inflammatory response and promote strong antioxidant support.
However, the ingredient is limited because of its poor solubility and bioavailability. Encapsulation of curcumin in nanoparticle-based delivery systems such as liposomes holds promise to overcome this limitation.
In the present study, researchers found promising effects of curcumin-loaded liposomes (PlexoZome) on A549 human lung adenocarcinoma cells.
The study reveals how liposomal curcumin (PlexoZome) may functionally suppress the proliferation, migration and colony formation of these cells while also drastically reducing the expression of multiple cancer marker proteins.
This work provides foundational data to develop a curcumin-based nanoformulation to be used as a potential therapy for non-small cell lung cancer (NSCLC).
Dr Kam Dua, Lead, Drug Delivery Node, Respiratory Pharmaceutical Research Team, Graduate School of Health, UTS, highlighted its therapeutic potential: “PlexoZome, an advanced liposomal curcumin formulation, shows immense promise in managing inflammation, combating oxidative stress and, most notably, addressing key characteristics of lung cancer."
"Its unique delivery system enhances curcumin's bioavailability, maximising its therapeutic impact on lung health."
"We are enthusiastic about our research partnership with Pharmako Biotechnologies and the potential this collaboration holds in making a meaningful difference in managing and treating respiratory conditions.”
“There are millions of people around the globe that are affected by this common, horrible disease. Couple this with more than 700 published studies on curcumin and its anticancer properties against lung cancer."
"It makes sense to explore advanced delivery technologies, namely liposomes, to accurately and precisely deliver this molecule. This study paves the way for further investigation of curcumin’s ability to fight lung cancer in humans,” said George Kokkinis, CEO and founder of Pharmako Biotechnologies.
